A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety

A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety

Background: Uterine leiomyosarcoma (uLMS) is characterized by aggressive behavior associated with a high risk of relapse and mortality. Several therapeutic agents have been employed in the treatment of metastatic disease, with a poor objective response rate. Pazopanib, approved in 2012, is a multi-t...

Full description

Bibliographic Details
Main Authors: Mara Mantiero, Marta Bini, Maggie Polignano, Luca Porcu, Roberta Sanfilippo, Chiara Fabbroni, Gabriella Parma, Mariateresa Lapresa, Carmelo Calidona, Cecilia Silvestri, Andrea Franza, Francesco Raspagliesi, Nicoletta Colombo, Monika Ducceschi
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Cancers
Subjects:
uterine leyomiosarcoma
pazopanib
effectiveness
safety
survival
Online Access:https://www.mdpi.com/2072-6694/16/1/192

Internet

https://www.mdpi.com/2072-6694/16/1/192

Similar Items